title: Neuroprotection: extrapolating from neurologic diseases to the eye.
abstract: OBJECTIVE
  To review the current status of neuroprotection in ophthalmic disease.
  
  
  METHODS
  Perspective.
  
  
  METHODS
  Published and unpublished data on neuroprotection in neurologic and ophthalmologic diseases were reviewed and interpreted.
  
  
  RESULTS
  Almost all clinical studies of neuroprotection in neurologic and ophthalmologic disease so far have failed to show efficacy, despite encouraging preclinical studies.
  
  
  CONCLUSIONS
  Achievement of consensus on how to design and execute translational research in neuroprotection in ophthalmic disease would optimize the use of resources and would hasten the development and approval of effective neuroprotective agents.
authors.affiliation: Department of Ophthalmology, University of Auckland Medical School, Auckland, New Zealand. helendm@gmail.com
authors.forename: Helen V
authors.initials: HV
authors.lastname: Danesh-Meyer
authors.forename: Leonard A
authors.initials: LA
authors.lastname: Levin
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D023381:Endpoint Determination; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005902:Glaucoma, Open-Angle / Q000517:prevention & control*; D006801:Humans; D008559:Memantine / Q000627:therapeutic use; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors; D009422:Nervous System Diseases / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009901:Optic Nerve Diseases / Q000188:drug therapy*; D019782:Riluzole / Q000627:therapeutic use
chemical_list: D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents; D016202:N-Methylaspartate; D019782:Riluzole; D008559:Memantine